Laigo Bio expands seed round for precision therapies
Utrecht-based biotech company Laigo Bio has completed the second close of its seed funding round, strengthening its financial position to advance a new generation of targeted therapies based on protein degradation. The fresh capital will allow the company to accelerate preclinical development, expand its scientific team and deepen collaborations with academic and industry partners.
Advancing targeted protein degradation
Laigo Bio focuses on harnessing the body’s own cellular machinery to selectively remove disease-causing proteins. This emerging field of targeted protein degradation goes beyond traditional small-molecule drugs, which typically inhibit protein function but do not eliminate the proteins themselves.
By designing molecules that tag harmful proteins for destruction, Laigo Bio aims to address conditions that have long been considered “undruggable”. Such an approach has the potential to transform treatment options in areas including oncology, neurodegenerative diseases and severe inflammatory disorders.
Strengthening the biotech ecosystem in Utrecht
The successful second close of the seed round highlights growing investor confidence in European biotech innovation and the Dutch life sciences ecosystem. Utrecht has been emerging as a hub for biotechnology and translational research, supported by leading universities, medical centers and specialized investors.
With this extended seed funding, Laigo Bio is expected to scale its research platform, refine its drug discovery pipeline and prepare its most promising candidates for future clinical development. The company’s work aligns with a broader industry shift toward more precise, mechanism-based therapies that can offer improved efficacy and reduced side effects for patients.
Next steps for Laigo Bio
The new investment will be directed toward validating key targets, expanding proprietary degrader molecules and building strategic partnerships to support eventual clinical trials. As competition intensifies in the protein degradation space, Laigo Bio aims to differentiate itself with a focused therapeutic strategy and robust scientific foundation.